Intricate technical design of the Sniper Balloon Occlusion Microcatheter allows for easy navigation through small complex vascular structures providing enhanced reach to distal target sites.

What is Pressure-Directed Embolization?

The Sniper’s balloon occludes the vessel to alter blood flow-dynamics using pressure-directed embolization. This increases therapeutic agent delivery into target areas while protecting surrounding healthy tissue. 1,2

Clinical Summary

Conventional vs. Balloon Occluded Transcatheter Arterial Chemoembolization (TACE)*.

Lipiodol® Filling

(Two studies totaling 143 patients)3,4

Complete Tumor Response

(Meta analysis of three studies totaling 221 patients)5,6,7,8

Survival

(One study with 62 patients)7

Designing Performance. Delivering Precision.

Sniper Product Family

Designed for arterial embolization procedures such as:

  • Transarterial Embolization (TAE)
  • Transarterial Chemoembolization (TACE)
  • Radioembolization (Y-90)
  • Arteriovenous Malformation (AVM)
  • Prostate Artery Embolization (PAE)
  • Renal Angiomyolipoma (AML)
  • Gastrointestional Bleads

Designed for arterial embolization procedures such as:

  • Transarterial Embolization (TAE)
  • Transarterial Chemoembolization (TACE)
  • Radioembolization (Y-90)
  • Arteriovenous Malformation (AVM)
  • Prostate Artery Embolization (PAE)
  • Gastrointestional Bleads

Compatible with the delivery of *:

 

  • Lipiodol®
  • Glue (n-bCA)
  • Coils up to 0.018″
  • Gelfoam
  • Dimethyl Sulfoxide (DMSO)
  • Spherical particles up to 900 μm

 

*See Sniper Chemical Compatibility Statement Letter MK-0351 below. Embolx does not make any claims; for information purposes only. 

Sniper Resource Center

  1. Rose S, Halstead G, Narsinh K. Pressure-Directed Embolization of Hepatic Arteries in a Porcine Model Using a Temporary Occlusion Balloon Microcatheter: Proof of Concept. Cardiovasc Intervent Radiol (2017) 40: 1769.
  2. Isaacson A, Hartman T, Bagla S, Burke C. Initial Experience with Balloon-Occlusion Prostatic Artery Embolization. J Vasc Interv Radiol (2018) 29: 85-89.
  3. Maruyama M, Yoshizako T, Nakamura T, et al. Initial Experience with Balloon-Occluded Trans-catheter Arterial Chemoembolization (B-TACE) for Hepatocellular Carcinoma. Cardiovasc Intervent Radiol (2016) 39: 359-366.
  4. Irie T, Kuramochi M, Takahashi N. Dense Accumulation of Lipiodol Emulsion in Hepatocellular Carcinoma Nodules during Selective Balloon-occluded Transarterial Chemoembolization: Measurement of Balloon-occluded Arterial Stump Pressure. Cariovasc Intervent Radiol (2013) 36: 706-713.
  5. Masahiro O, Takayasu K, Hirayama M, et al. Efficacy of a microballoon catheter in transarterial chemoembolization using miriplatin, a lipophilic anticancer drug: short-term results. Hepatology Research (2016) 46: E60-69.
  6. Arai H, Abe T, Takayama H, et al. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatology Research (2015) 45: 663-666.
  7. Irie T, Kuramochi M, Kamoshida T, Takahashi N. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: retrospective comparison with conventional super-selective TACE. Hepatology Research (2016) 46: 209-214.
  8. Stephan Ogenstad, Statogen Consulting LLC. Meta-analysis of clinical studies performed by: Masahiro (2016) ref. 5, Arai (2015) ref. 6, and Irie (2016) ref. 7. Analysis on file at Embolx, Inc. (2017).